Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L.
van der Heijde D, et al.
Rheumatology (Oxford). 2020 Jun 1;59(6):1325-1334. doi: 10.1093/rheumatology/kez420.
Rheumatology (Oxford). 2020.
PMID: 31586420
Free PMC article.
Clinical Trial.
METHODS: Patients with active PsA, stratified by prior anti-TNF use (naive or inadequate response), were randomized to s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at we …
METHODS: Patients with active PsA, stratified by prior anti-TNF use (naive or inadequate response), were randomized to s.c. secukinumab 300 …